Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2- ethyl-3-hydroxypyridin-4-one (CP117) in the rat

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 332-339

  Choudhury, Ruksana ^b   Epemolu, Rafiu O ^b   Rai, Bijaya L ^b   Hider, Robert C ^b   Singh, Surinder ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; CP 117; DEFEROXAMINE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG SYNTHESIS; DRUG URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0030933588     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. S. Singh, and R. C. Hider: Therapeutic iron-chelating agents. In "Free Radical Damage and Its Control" (C. A. Rice-Evans and R. H. Burdon, eds.), pp. 189-213. Elsevier, Amsterdam, 1994.
2. R. C. Hider, S. Singh, J. B. Porter, and E. R. Huehns: The development of hydroxypyridin-4-ones as orally active iron chelators. Ann. N. Y. Acad. Sci. 612, 327-338 (1990).
3. M. J. Pippard, E. A. Letsky, S. T. Callender, and D. J. Weatherall: Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1, 1178-1180 (1978).
4. R. C. Hider, S. Singh, and J. B. Porter: Iron chelating agents with clinical potential. Proc. R. Soc. Edinburgh 99B, 137-168 (1992).
5. B. Halliwell, and J. M. C. Gutteridge: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1-14 (1984).
6. D. J. Weatherall, and J. B. Clegg: "The Thalassaemia Syndromes," 3rd ed. Blackwell Scientific Press, Oxford, UK, 1981.
7. R. C. Hider, and A. D. Hall: Iron chelating agents in medicine. The application of bidentate hydroxypyridin-4-ones. In "Perspectives on Bioinorganic Chemistry" (R. W. Hay, J. R. Dilworth, and K. B. Nolan, eds.), vol. 1, pp. 209-253. JAI Press Ltd., London, 1991.
8. R. D. Propper, B. Cooper, R. R. Rufo, A. W. Nienhuis, W. F. Anderson, H. F. Bunn, H. R. Rosenthal, and D. G. Nathan: Continuous subcutaneous administration of desferrioxamine in thalassaemia major. N. Engl. J. Med. 297, 418-423 (1977).
9. P. Lee, N. Mohammed, L. Marshall, R. D. Abeysinghe, R. C. Hider, J. B. Porter, and S. Singh: Intravenous infusion pharmacokinetics of desferrioxamine in thalassemic patients. Drug Metab. Dispos. 21, 640-644 (1993).
10. R. C. Hider, J. B. Porter, and S. Singh: The design of therapeutically useful iron chelators. In "The Development of Iron Chelators for Clinical Use" (R. J. Bergeron and G. M. Brittenham, eds.), pp. 353-371. CRC Press, Boca Raton, FL, 1994.
11. J. B. Porter, E. R. Huehns, and R. C. Hider: The development of iron chelating drugs. Ballière's Clin. Haematol. 2, 257-292 (1989).
12. J. B. Porter, R. D. Abeysinghe, C. Barra, K. P. Hoyes, P. N. Brooks, E. R. Huehns, and R. C. Hider: Oral efficacy and metabolism of 1,2-diethyl-3-hydroxypyridin-4-one in thalassaemia major. Blood 78, 2071 (abstr.) (1991).
13. J. B. Porter, J. Morgan, K. P. Hoyes, L. C. Burke, E. R. Huehns, and R. C. Hider: Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76, 2389-2396 (1990).
14. J. B. Porter, K. P. Hoyes, R. D. Abeysinghe, P. N. Brooks, E. R. Huehns, and R. C. Hider: Comparison of the subacute toxicity and efficacy of orally active 3-hydroxypyridin-4-one iron chelators. Blood 78, 2727-2734 (1990).
15. S. Singh, R. O. Epemolu, P. S. Dobbin, G. S. Tilbrook, B. L. Ellis, L. A. Damani, and R. C. Hider: Urinary metabolic profiles in man and rat of 1,2-dimethyl and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab. Dispos. 20, 256-261 (1992).
16. S. Singh, R. O. Epemolu, R. Ackerman, J. B. Porter, and R. C. Hider: Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolism. 3rd NIH-Sponsored Symposium on "The Development of Iron Chelators for Clinical Use," Abstract 52, Gainsville, FL, 1992.
17. S. Singh: Therapeutically useful iron chelators. Chem. Indus. 452-455 (1994).
18. R. Choudhury, and S. Singh: Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat. Drug Metab. Dispos. 23, 314-320 (1995).
19. P. S. Dobbin, R. C. Hider, A. D. Hall, P. D. Taylor, P. Sarpong, J. B. Porter, G. Xiao, and D. van der Helm: Synthesis, physiochemical properties and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4-(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36, 2448-2458 (1993).
20. 3] and glucuronide conjugate [CP94-Gluc] in serum and urine of thalassaemic patients. J. Pharm. Biomed. Anal. 12, 923-930 (1994).
21. M. J. Pippard, D. K. Johnson, and C. A. Finch: A rapid assay for evaluation of iron chelating agents in rats. Blood 58, 685-691 (1981).
22. C. Hershko and D. J. Weatherall: Iron chelating therapy. CRC Crit. Rev. Clin. Lab. Sci. 26, 303-345 (1988).